Clinical Trial Update: Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV [Phase 2]

View source ↗

Summary

Phase 2B dose-ranging study evaluating Locteron in combination with ribavirin for chronic hepatitis C has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Locteron
• Ribavirin (ribavirin)

Snippet

Sponsor: Biolex Therapeutics, Inc. | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED